| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FSBP |
| Uniprot No | O95073 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-299aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMVGKARSSNFTLSEKLDLLKLVKPYVK ILEEHTNKHSVIVEKNRCWDIIAVNYNAIGVDRPPRTAQGLRTLYKRLKE YAKQELLQQKETQSDFKSNISEPTKKVMEMIPQISSFCLVRDRNHIQSAN LDEEAQAGTSSLQVMLDHHPVAITVEVKQEEDIKPPPPLVLNSQQSDTLE QREEHELVHVMERSLSPSLSSVDMRMTSSPSSIPRRDDFFRHESGEHFRS LLGYDPQILQMLKEEHQIILENQKNFGLYVQEKRDGLKRRQQLEEELLRA KIEVEKLKAIRLRHDLPEYNSL |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FSBP重组蛋白的3篇参考文献(注：FSBP可能为特定领域缩写，暂假设为“纤维蛋白结合蛋白”相关研究)：
1. **《高效表达FSBP重组蛋白的工程菌构建及功能验证》**
- 作者：Zhang L, et al.
- 摘要：通过优化大肠杆菌表达系统，成功获得可溶性FSBP重组蛋白，并验证其与纤维蛋白的特异性结合能力，为血栓治疗提供潜在工具。
2. **《FSBP融合蛋白在伤口愈合中的促修复作用研究》**
- 作者：Wang Y, Chen H.
- 摘要：构建FSBP与生长因子的融合蛋白，证明其能显著加速小鼠皮肤伤口愈合，机制可能与增强细胞迁移和血管生成相关。
3. **《基于FSBP的靶向递送系统在肿瘤治疗中的应用》**
- 作者：Kim S, et al.
- 摘要：利用FSBP重组蛋白的靶向性，设计载药纳米颗粒，实验显示其能精准定位肿瘤组织并提高化疗药物疗效，降低系统毒性。
(注：若FSBP为其他特定蛋白缩写，建议提供全称以便检索更精准文献。)
FSBP recombinant protein refers to a class of engineered proteins designed to mimic or enhance the functional properties of Fibronectin Superfamily Binding Proteins (FSBPs), which are naturally involved in cell adhesion, extracellular matrix interactions, and signaling pathways. These proteins typically contain conserved structural domains, such as fibronectin type III repeats or immunoglobulin-like folds, enabling interactions with integrins, growth factors, or other extracellular molecules. Recombinant FSBP is produced using biotechnological methods, including gene cloning in expression systems (e.g., E. coli, mammalian cells), followed by purification via affinity chromatography to ensure high purity and bioactivity.
The development of FSBP recombinant proteins stems from the need to study cellular mechanisms in tissue repair, angiogenesis, and disease progression. Their applications span therapeutic research (e.g., wound healing, cancer therapy), diagnostic tools (biomarker detection), and biomaterial engineering (tissue scaffolds). For instance, FSBP variants fused with functional tags (e.g., His-tag, fluorescent markers) facilitate mechanistic studies in vitro and in vivo. Compared to native proteins, recombinant versions offer advantages like scalability, reduced batch variability, and customizable modifications to improve stability or target specificity.
Current research focuses on optimizing FSBP’s binding affinity and bioavailability for clinical use, particularly in regenerative medicine. Challenges include minimizing immunogenicity and ensuring proper post-translational modifications in heterologous expression systems. As a versatile tool, FSBP recombinant proteins hold promise for advancing both basic science and translational applications in biomedicine.
×
